These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 16967134)

  • 1. [Isolated effect of the monoclonal antibody trastuzumab (Herceptin) in a patient with local recurrence of breast carcinoma with HER-2 hyperexpression. ].
    Del Giglio A
    Rev Assoc Med Bras (1992); 2006; 52(4):202. PubMed ID: 16967134
    [No Abstract]   [Full Text] [Related]  

  • 2. [Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].
    Mallmann P
    Internist (Berl); 2006 Nov; 47(11):1183-5. PubMed ID: 17048017
    [No Abstract]   [Full Text] [Related]  

  • 3. What is the mechanism of progression with trastuzumab treatment--escape or resistance?
    Sendur MA; Aksoy S; Özdemir NY; Zengin N; Altundağ K
    Asian Pac J Cancer Prev; 2012; 13(11):5915-6. PubMed ID: 23317282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines.
    Ginestier C; Adélaïde J; Gonçalvès A; Repellini L; Sircoulomb F; Letessier A; Finetti P; Geneix J; Charafe-Jauffret E; Bertucci F; Jacquemier J; Viens P; Birnbaum D
    Oncogene; 2007 Nov; 26(50):7163-9. PubMed ID: 17525746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unusual problems in breast cancer and a rare lung cancer case. Case 1. Clinical complete response of breast cancer metastases after trastuzumab-based immunotherapy.
    Tonini G; Vincenzi B; Santini D; Avvisati G; La Cesa A; Baldi A
    J Clin Oncol; 2003 Jun; 21(11):2215-6. PubMed ID: 12775749
    [No Abstract]   [Full Text] [Related]  

  • 6. Effectiveness of Trastuzumab (Herceptin) in a patient with locally recurrent breast cancer after cardiac failure caused by severe cytotoxic pretreatment.
    Gerber B; Krause A; Markmann S; Reimer T; Fietkau R; Müller H
    Oncology; 2001; 61(4):271-4. PubMed ID: 11721173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
    Baselga J; Perez EA; Pienkowski T; Bell R
    Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy and herceptin for HER2(+) metastatic breast cancer: the best drug?
    Livingston RB; Esteva FJ
    Oncologist; 2001; 6(4):315-6. PubMed ID: 11524548
    [No Abstract]   [Full Text] [Related]  

  • 9. Synthesis and evaluation of antiproliferative activity of a geldanamycin-Herceptin immunoconjugate.
    Mandler R; Dadachova E; Brechbiel JK; Waldmann TA; Brechbiel MW
    Bioorg Med Chem Lett; 2000 May; 10(10):1025-8. PubMed ID: 10843208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibody therapy for breast cancer: herceptin.
    Finn RS; Slamon DJ
    Cancer Chemother Biol Response Modif; 2003; 21():223-33. PubMed ID: 15338747
    [No Abstract]   [Full Text] [Related]  

  • 11. Trastuzumab: is the new evidence revolutionary?
    Munshi A; Singh P; Jalali R
    J Cancer Res Ther; 2006; 2(3):144-6. PubMed ID: 17998695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trastuzumab as single agent therapy for HER2-positive metastatic breast cancer.
    Rastogi P; Davidson NE
    Onkologie; 2010; 33(8-9):420-1. PubMed ID: 20838056
    [No Abstract]   [Full Text] [Related]  

  • 13. [The requirements to clinicopathology about targeted therapy for breast cancer].
    Jiang ZF; Shen G
    Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):435-7. PubMed ID: 17845752
    [No Abstract]   [Full Text] [Related]  

  • 14. Her-2/neu and breast cancer.
    Kaptain S; Tan LK; Chen B
    Diagn Mol Pathol; 2001 Sep; 10(3):139-52. PubMed ID: 11552716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancer.
    Morris SR; Carey LA
    Oncology (Williston Park); 2006 Dec; 20(14):1763-71; discussion 1771-2, 1774-6. PubMed ID: 17263127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.
    Shak S
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):71-7. PubMed ID: 10482196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Trastuzumab (Herceptin) in the adjuvant treatment of HER-2-positive early breast cancer].
    Láng I; Hitre E
    Magy Onkol; 2006; 50(4):293-302. PubMed ID: 17216002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab: mechanisms of resistance and therapeutic opportunities.
    Calabrich A; Fernandes Gdos S; Katz A
    Oncology (Williston Park); 2008 Oct; 22(11):1250-8; discussion 1259, 1263. PubMed ID: 18980023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group.
    Bookman MA; Darcy KM; Clarke-Pearson D; Boothby RA; Horowitz IR
    J Clin Oncol; 2003 Jan; 21(2):283-90. PubMed ID: 12525520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Trastuzumab, a new treatment approach in breast carcinoma].
    Raab G; Eiermann W
    Internist (Berl); 2001 Jun; 42(6):835-40, 842. PubMed ID: 11449630
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.